Ask about this productRelated genes to: SLC43A1 antibody
- Gene:
- SLC43A1 NIH gene
- Name:
- solute carrier family 43 member 1
- Previous symbol:
- POV1
- Synonyms:
- R00504, PB39
- Chromosome:
- 11q12.1
- Locus Type:
- gene with protein product
- Date approved:
- 1998-10-02
- Date modifiied:
- 2016-02-17
Related products to: SLC43A1 antibody
Related articles to: SLC43A1 antibody
- To investigate the impact of prenatal fear stress on placental amino acid transport and emotion and cognition development in offspring rats. - Source: PubMed
DU ZhixinWang YueyangYang LipingHou JunlinSun JianhuaFan PengbeiWang YaohuiLi Xiaolin - Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States, with a five-year survival rate of 65%. Oxaliplatin was the first platinum drug shown to improve CRC patient outcomes and is now a common adjuvant therapy for advanced disease, yet 90% of patients develop resistance. Oxaliplatin was developed as a third-generation derivative of cisplatin, but recent evidence points to divergent modes of action. Here, genome-wide CRISPR activation and knockout screens were conducted to identify genetic changes that confer resistance to oxaliplatin in two CRC cell lines with distinct molecular backgrounds (SW620 and RKO). Guide RNAs corresponding to the neutral amino acid transporter (LAT3) were the most significantly enriched in knockout screens and depleted in activation screens, suggesting a potential role for LAT3 in modulating oxaliplatin resistance. CRISPR knockout and overexpression of LAT3 in SW620 and RKO cell lines confirm increased resistance or sensitivity to oxaliplatin, respectively. Further analysis demonstrates that increased LAT3 levels corrrelate with increased intracellular levels of oxaliplatin, increased levels of DNA-platinum adducts and DNA damage, demonstrating that enhanced LAT3-mediated uptake of oxaliplatin can exert its expected mechanism of action and induce cytotoxicity. These findings may lead to a better understanding of oxaliplatin's mode of action in CRC and can provide new insights into the interplay between essential nutrient uptake and drug transport. - Source: PubMed
Publication date: 2025/04/24
Pawar N RWade H MJackson ZPoungpeth NMitchell A VJewell C PChan DRobey R WBatista P JJenkins L MGottesman M M - has been used as a traditional Oriental medicinal herb. This research investigates the potential of ginsenosides, bioactive phyto compounds derived from , as ligands of the solute carrier (SLC) family, including SLC3A2, SLC7A6, SLC7A11, SLC7A5, SLC7A8, SLC43A1, LCN2, SLC7A9, SLC7A7, and SLC7A10 proteins-which are overexpressed in various cancers and linked to metastasis. Using molecular docking (MD), ginsenosides (Km, Ro, compound K (CK), Rk1, and Ra1) with high binding affinities to SLC3A2 were identified, exhibiting binding energies of -9.3, -9.1, -8.7, -8.0, and -7.7 kcal/mol, respectively. Further molecular dynamics simulations (MDSs) conducted using GROMACS revealed improved stability, flexibility, and dynamic behavior of the selected ginsenosides, predicting their potential as natural ligands to bind with SLC3A2. Though this computational prediction underscores these ginsenosides as promising candidates as natural ligands to bind and interact with SLC family proteins during anti-cancer therapies, further in vitro and in vivo studies are needed to validate these interactions and anti-cancer effects. - Source: PubMed
Publication date: 2025/06/04
Lu Jing - Branched-chain amino acids (BCAA) metabolism is significantly associated with osteoarthritis (OA), but the specific mechanism of BCAA related genes (BCAA-RGs) in OA is still unclear. Therefore, this research intended to identify potential biomarkers and mechanisms of action of BCAA-RGs in OA tissues. - Source: PubMed
Publication date: 2025/05/26
ZhaYang Xiao-ZhiChen Yan-XiongHua Wen-DaBai Zheng-LinJin Yun-PengZhao Xing-WenLiu Quan-FuMeng Zeng-Dong - Androgen deprivation therapy (ADT) resistance is closely associated with altered AR status. Aberrant AR expression is critical for the induction of ADT resistance, necessitating the identification of an anti-PCa target independent of AR expression. - Source: PubMed
Publication date: 2024/10/16
Xie HailongDan MingjiangCen YiNing JingSun ChongZhu GuangbinFeng ShouruiWang HaiyanPu Jinxian